<DOC>
	<DOCNO>NCT01952015</DOCNO>
	<brief_summary>The purpose study assess efficacy safety data secukinumab Japanese subject generalize pustular psoriasis ( GPP ) . This study expect support filing secukinumab indication pustular psoriasis Japan .</brief_summary>
	<brief_title>Study Assess Efficacy , Safety Tolerability Secukinumab Japanese Subjects With Generalized Pustular Psoriasis ( GPP )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>At baseline , presence GPP classify basis criterion diagnosis GPP Japanese Dermatological Association ( JDA ) At baseline , erythema area pustule ≥ 10 % Erythrodermic , guttate psoriasis , subcorneal pustular dermatosis screening . At baseline , : total score JDA severity index GPP ≥ 14 Druginduced psoriasis Ongoing use prohibit psoriasis treatment . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>generalize pustular psoriasis</keyword>
</DOC>